

ORIGINAL ARTICLE

Evaluation of Lens Culinaris Agglutinin-Reactive α -Fetoprotein in Diagnosis of Malignant Tumors

Zhongwei Jia, Jinxing Xia, Qiong Lu

Department of Clinical Laboratory, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

SUMMARY

Background: To assess the potential of AFP-L3% for the utility to diagnose malignant tumors.

Methods: AFP-L3 was concentrated from clinically-collected serum samples via the Hotgen Biotech glycosyl capture spin columns and then measured through the protein microarrays. The levels of AFP and AFP-L3 were detected by electrochemiluminescence immunoassay. In this retrospective study, 266 patients with the level of serum AFP-L3 over 1 ng/mL were recruited from December 2014 through April 2019. Among them, 155 patients were clinically diagnosed/confirmed with malignant tumors, including 101 hepatocellular carcinomas, 47 stomach malignant tumors, and 7 other malignant tumors; and the rest of 111 patients were nonmalignant tumors.

Results: Patients with serum AFP-L3 level of greater than 1 ng/mL were mainly detected in hepatic diseases, including hepatocellular carcinoma, cirrhosis and chronic hepatitis. In patients with no tumors, the levels of serum AFP-L3 over 1 ng/mL were only observed in liver disease. The levels of AFP-L3 in blood were substantially greater in patients with HCC. Among the malignant tumor patients with the level of serum AFP-L3 over 1 ng/mL, HCC accounted for 60%, gastric cancer for nearly 40%. The AFP, AFP-L3, and AFP-L3% in blood were increased significantly in patients with liver malignancy, chronic liver disease, and cirrhosis. However, the elevation of AFP-L3 and AFP-L3% in the malignant cohort was more evident than that in the nonmalignant counterpart.

Conclusions: AFP-L3 is likely to contribute to the differential diagnosis of HCC as well as other hepatic diseases. AFP-L3% is a reliable indicator for diagnosing benign and malignant tumors.

(Clin. Lab. 2022;68:xx-xx. DOI: 10.7754/Clin.Lab.2022.211219)

Correspondence:

Zhongwei Jia
Department of Clinical Laboratory
First Affiliated Hospital of Anhui Medical University
Hefei
Anhui 230022
China
Email: jjalu930@163.com

KEYWORDS

hepatocellular carcinoma, malignant tumors, liver cirrhosis, gastric cancer, non-neoplastic, AFP-L3%

INTRODUCTION

Hepatocellular carcinoma (HCC) belongs to one of the most common malignant tumors [1-4]. Once diagnosed, patients usually have reached the middle or late tumor stage, with poor therapeutic effect and high mortality rate. Previous studies illustrate that continuous serum α -fetoprotein (AFP) level with 400 ng/mL or more exhibits a significantly high specificity to diagnose primary HCC [5], the levels of AFP were observed to correlate with the velocity of tumor growth [6]. However, it turns out that in clinic the levels of AFP in blood within certain patients with hepatic diseases were greater than 400

ng/mL, but their clinical diagnosis was nonmalignant diseases (e.g., chronic hepatitis and cirrhosis) [7-9]. Studies also have found that AFP from different sources presented differential affinity to Lens culinaris agglutinin [10]. Based on its difference, AFP is divided into 3 categories: AFP binding to Lens culinaris agglutinin_1 (AFP_L1), Lens culinaris agglutinin_2 (AFP_L2), and Lens culinaris agglutinin_3 (AFP-L3) [8]. It has demonstrated that AFP-L3 was closely related to primary HCC, which can contribute to the definite diagnosis of HCC [11-13]. The percentage of AFP-L3 (AFP-L3%) has newly been proposed as a reliable indicator for diagnosing malignant tumors with a higher diagnostic value in HCC than AFP. Previous research has determined the serum AFP-L3 level of 10% to be a cut-off readout to diagnose HCC [14-16].

The concentration of serum AFP-L3 in healthy populations is remarkably low and cannot be detected using the current common method in clinic which has a maximum sensitivity of 0.605 ng/mL. This study investigated patients with a level of serum AFP-L3 over 1 ng/mL, aiming to understand the potential links of the AFP-L3 in blood to its related diseases, to explore the differences of AFP_L3% values in patients with or without malignant tumors, and to explore its potential clinical applications.

MATERIALS AND METHODS

Research subjects

Clinically-collected blood samples were drawn from 266 patients assessed for hepatic tumors or other diseases at the First Affiliated Hospital of Anhui Medical University from December 2014 to April 2019 under the Institutional Review Board-approved protocol. The clinical and laboratory information on these recruited subjects was retrospectively ascertained from relevant medical records. All subjects in this study signed an informed consent and their medical documents were critically reviewed to confirm their medical history as well as physical checks and laboratory examinations.

Of the 266 patients, 202 males and 64 females both with levels of AFP-L3 over 1 ng/mL were included, with the age of 25 - 87 (54.94 ± 12.51) years old. Among them, 155 patients were clinically diagnosed with malignant tumors, including 101 HCCs, 47 stomach malignant tumors, and 7 other malignant tumors; while the other 111 patients had nonmalignant tumors, including 69 with cirrhosis, 35 with chronic hepatitis B, and 7 with other types of hepatitis. Patients were chosen who had specimens available that had been collected after disease diagnoses yet before any therapies.

Measurement for AFP-L3 percentages

Blood samples were collected when diagnosed and before any interventions and then frozen at -80°C until use. The levels of AFP and AFP-L3 were detected using AFP testing reagents supplied by Roche (Germany)

using an electrochemical luminescence analyzer (e601 module, Roche, Germany). Prior to AFP-L3 detection, the blood samples need to be pre-processed. Every AFP-L3 portion supernatant was separated from the blood samples via a Hotgen Biotech glycosyl capture spin-column. The primary mechanism of the spin-column was that the spin-column was first pre-loaded with Lens culinaris agglutinin to have the fucosylated fraction thoroughly captured, followed by a simple sugar added to compete with the aforementioned captured fucosylated fraction to bind to Lens culinaris agglutinin. Hence, the fucosylated fraction in the sera, the AFP-L3 included, was consequently eluted from the spin-column. After cleaning, free AFP was removed, and AFP-L3 was obtained by elution and centrifugation. Then the Roche electrochemical luminescence analyzer was used to detect the contents of total AFP and AFP-L3. The AFP-L3 percentages were calculated accordingly, and the maximum sensitivity for this assay of AFP-L3 was set to 0.605 ng/mL.

Statistical analysis

All data were performed using SPSS19.0 software and GraphPad Prism (GraphPad software). Results were statistically analyzed using nonparametric tests (Mann-Whitney U) to compare differences among the groups. Differences of $p < 0.05$ were considered statistically significant.

RESULTS

Subject features

HCC in patients with the level of serum AFP-L3 over 1 ng/mL accounted for only 38%, as shown in Table 1. Other diseases were found at 41.7% in non-neoplastic liver diseases in the total detected cases, including 25.9% cirrhosis, 13.2% chronic hepatitis B, and 2.6% other hepatitis; other tumors presented at 20.3% within all the detected subjects, among which the gastric cancer was predominant (17.7%). Similarly, these levels were mainly found associated with liver diseases, and males were significantly higher than females (76% vs. 24%).

Comparison of AFP, AFP-L3, as well as AFP-L3% in different groups of diseases

The serum levels of AFP-L3 were remarkably elevated in patients with HCC compared to those with other cancers or non-neoplastic diseases. However, the amount of serum AFP and AFP-L3 was significantly increased in a small number of patients with nonmalignant tumors. It was observed that the increase of AFP-L3 in patients with gastric cancer was not comparable to that in HCC patients, whereas the value of AFP-L3% was similar to that in patients with HCC (Figure 1).

Table1. Primary characteristics of patients with the level of AFP-L3 over 1 ng/mL in blood (n = 266).

Variables	n (%)
Age (years)	
Mean (range)	55 (25 - 87)
Gender	
Male	202 (75.97)
Female	64 (24.06)
Disease	
Malignant tumor	155 (58.27)
Hepatocellular carcinoma	101 (37.97)
Gastric cancer	47 (17.67)
Other tumors	7 (2.63)
Nonmalignant tumor	111 (41.73)
Liver cirrhosis	69 (25.94)
Chronic hepatitis B	35 (13.16)
Non-hepatitis B	7 (2.63)

Comparison of AFP, AFP-L3, as well as AFP-L3% in malignant and nonmalignant tumor groups

AFP-L3% was more pronounced than AFP as well as AFP-L3 in distinguishing malignant and nonmalignant tumors. However, a small percentage of nonmalignant patients possessed the AFP-L3% value of more than 10% (Figure 2).

DISCUSSION

In clinic, the diagnosis of liver cancers primarily depends on the detection of serum AFP, imaging, and pathological examinations. The AFP concentration over 400 ng/mL was regarded to be ideal to diagnose HCC [5]. However, during the routine clinical examinations, the serum AFP was usually found to be more than 400 ng/mL in some patients who eventually were not clinically diagnosed as HCC, since cirrhosis, chronic hepatitis B, and even other types of tumors may also cause increased AFP. On the contrary, patients with mild or moderate AFP elevation had imaging or pathological evidence for tumors, thus were actually diagnosed to be HCC. The AFP-L3% is newly proposed to be a potential indicator for diagnosing malignant tumors, which increasingly reveals a higher diagnostic value in HCC than AFP [14,15]. The links of the pre-processed AFP-L3 to cancer etiology and progression have been investigated for a couple of years. However, this field has not been thoroughly explored to date [17].

It was believed that the AFP-L3 portion was much more sensitive to diagnose early-stage and/or small-sized HCCs when compared with AFP [7,18,19]. It was also reported to be reliably specific for HCC and was able to imply cancer features such as poor differentiation and/

or cancerous aggression [20-23]. We found that the low sensitivity (AFP-L3 < 0.605 ng/mL) of the AFP-L3 to predict AFP-negative (AFP < 7 ng/mL) patients was consistent with the previous reports [24]. The results suggest that AFP-L3 might show confined applications in terms of being an independent diagnostic biomarker for HCC, considering a remarkable fraction of patients with HCCs would be excluded by AFP.

In the present study, it is shown that HCC in patients with the level of serum AFP-L3 over 1 ng/mL barely accounted for 38%, whereas the other non-neoplastic liver diseases accounted for nearly 40% in all the detected subjects. Our findings suggest that liver diseases should be first taken into account when AFP-L3 is larger than 1 ng/mL. Once liver diseases are ruled out, the patient would then be put on high alert for tumors in other systems, especially for gastric cancers. Moreover, AFP and AFP-L3 were substantially greater in the sera of HCC patients than those with other tumors and non-neoplastic diseases. Therefore, as for patients who suffer from chronic hepatitis or cirrhosis whose AFP and AFP-L3 are mildly elevated in blood, regularly monitoring of AFP-L3 in blood is recommended; once a significant increase of the blood AFP-L3 occurs in a short period of time, liver carcinomatous changes should be under consideration. Some scholars thought that AFP-L3 measurement predicted the potential of biological malignancy of HCC prior to any therapy. To be noted, the AFP-L3 was also believed to contribute to the prediction of HCC relapse post curative therapy much earlier compared to the AFP detection [25-28].

Our data illustrate that AFP-L3% in the primary hepatic malignancy cohort was considerably higher compared with that in both chronic hepatitis B and cirrhosis counterparts. The increased AFP-L3% was highly associated




Figure 1. Comparison of AFP, AFP-L3, as well as AFP-L3% in the different groups of diseases as indicated.

with the degree of liver pathological changes of malignancy. Of note, we did observe several subjects in the cirrhosis and chronic hepatitis B groups with AFP of greater than 400 ng/mL but with the AFP-L3% of no more than 10%. Although this portion of patients were not eventually diagnosed clinically with liver cancers,

they should be highly recommended to continuously dynamically monitor AFP-L3%. If an evident elevation occurs in its serum level, the corresponding further detection should be done to diagnose HCC early and intervene timely. Finally, HCC should be considered in patients with chronic hepatitis B and/or cirrhosis, whose




Figure 2. Comparison of AFP, AFP-L3, as well as AFP-L3% in malignant tumor and nonmalignant tumor groups.

AFP-L3% index exceeds 10%. AFP, AFP-L3, as well as AFP-L3% have been observed to significantly increase in the sera of patients with HCC, cirrhosis, and chronic hepatic diseases. Nevertheless, the levels of AFP and AFP-L3% were substantially greater in the malignant cohort compared to those in the nonmalignant counterpart. Previous research has indicated that high levels of

AFP-L3% in blood predicted poor prognosis for patients with HCC [29].

In this study, a small number of nonmalignant tumor patients with AFP-L3% over 10% could not be clinically diagnosed as malignant tumors. It is believed that such patients were likely to be at high risk of malignant tumors, and the instant changes of AFP-L3% and imag-

ing examination should be monitored dynamically. Among the patients with malignant tumors and with the level of AFP-L3 over 1 ng/mL, HCC accounted for 60% and gastric cancer for nearly 40%. The increase of AFP-L3 in patients with gastric cancer was not as great as that in those with HCC; nonetheless, AFP-L3% was similar in all these subjects. The AFP-L3% of these patients can be used as the diagnosis, prognosis and post-operative evaluation index for gastric cancer. The reason why this many patients with gastric cancer express AFP-L3 is unclear. We hypothesized that one of the gastric malignancies would have liver metastasis, but the lesions are small or inconspicuous and not clinically diagnosed. Furthermore, this part of gastric malignant tumors might be able to produce and secrete additional AFP-L3. These assumptions, of course, remain to be validated. Previous research reported that serum AFP-L3 was able to significantly increase in patients who suffer from severe liver damage [30]. In that study, 4 cases of hepatitis E had AFP levels between 40 ng/mL and 100 ng/mL, among which 3 cases had AFP-L3% positively detected. Such a high positive rate is surprising, given that hepatitis E could cause acute and severe hepatitis. It was speculated that AFP-L3% could be used as a prognostic index of hepatitis E, which requires large size of samples and continuous follow-up to draw definite conclusions.

CONCLUSION

AFP-L3 is likely to contribute to differential diagnosis of HCC as well as other hepatic diseases, AFP-L3% is a reliable indicator for diagnosing benign and malignant tumors.

Acknowledgment:

This work has been supported by the Department of Education Anhui Province of China (Quality Project Grants No. 2016jyxm0532).

Declaration of Interest:

No conflicts of interest to declare.

References:

1. Wu M, Liu H, Liu Z, Liu C, Zhang A, Li N. Analysis of serum alpha-fetoprotein (AFP) and AFP-L3 levels by protein microarray. *J Int Med Res* 2018;46(10):4297-305. (PMID: 3011217)
2. Gao J, Song P. Combination of triple biomarkers AFP, AFP-L3, and PIVAKII for early detection of hepatocellular carcinoma in China: Expectation. *Drug Discov Ther* 2017;11(3):168-9. (PMID: 28757516)
3. Yen CW, Kuo YH, Wang JH, et al. Did AFP-L3 save ultrasonography in community screening? *Kaohsiung J Med Sci* 2018; 34(10):583-7. (PMID: 30309487)
4. Nguyen-Dinh SH, Do A, Pham TND, Dao DY, Nguy TN, Chen MS, Jr. High burden of hepatocellular carcinoma and viral hepatitis in Southern and Central Vietnam: Experience of a large tertiary referral center, 2010 to 2016. *World J Hepatol* 2018;10(1):116-23. (PMID: 29399285)
5. Hu B, Tian X, Sun J, Meng X. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis. *Int J Mol Sci* 2013;14(12): 23559-80. (PMID: 24317431)
6. Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. *World J Gastroenterol* 2016;22(1):232-52. (PMID: 26755873)
7. Choi JY, Jung SW, Kim HY, et al. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. *World J Gastroenterol* 2013;19(3):339-46. (PMID: 23372355)
8. Wang NY, Wang C, Li W, et al. Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation. *Asian Pac J Cancer Prev* 2014;15(4):1539-44. (PMID: 24641364)
9. Endo S, Watanabe Y, Abe Y, et al. Hepatic inflammatory pseudotumor associated with primary biliary cholangitis and elevated alpha-fetoprotein lectin 3 fraction mimicking hepatocellular carcinoma. *Surg Case Rep* 2018;4(1):114. (PMID: 30203247)
10. Okagawa Y, Takada K, Arihara Y, et al. Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells. *PLoS One* 2016;11(12): e0168355. (PMID: 27977808)
11. Park SJ, Jang JY, Jeong SW, et al. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. *Medicine (Baltimore)* 2017;96(11):e5811. (PMID: 28296720)
12. Seino S, Tsuchiya A, Watanabe Y, et al. Clinical outcome of hepatocellular carcinoma can be predicted by the expression of hepatic progenitor cell markers and serum tumour markers. *Oncotarget* 2018;9(31):21844-60. (PMID: 29774107)
13. Li B, Li B, Guo T, et al. The Clinical Values of Serum Markers in the Early Prediction of Hepatocellular Carcinoma. *Biomed Res Int* 2017;2017:5358615. (PMID: 28540298)
14. Hiraoka A, Nakahara H, Kawasaki H, et al. Huge pancreatic acinar cell carcinoma with high levels of AFP and fucosylated AFP (AFP-L3). *Intern Med* 2012;51(11):1341-9. (PMID: 22687839)
15. Zhang A, Skog S, Wang S, et al. A Chemiluminescent Protein Microarray Method for Determining the Seroglycoid Fucosylation Index. *Sci Rep* 2016;6:31132. (PMID: 27528397)
16. Wu CS, Lee TY, Chou RH, et al. Development of a highly sensitive glycan microarray for quantifying AFP-L3 for early prediction of hepatitis B virus-related hepatocellular carcinoma. *PLoS One* 2014;9(6):e99959. (PMID: 24927126)
17. Cheng J, Wang W, Zhang Y, et al. Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis. *PLoS One* 2014;9(1):e87011. (PMID: 24498011)

18. Tamura Y, Igarashi M, Kawai H, Suda T, Satomura S, Aoyagi Y. Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. *Dig Dis Sci* 2010;55(12):3576-83. (PMID: 20407827)
19. Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. *Hepatology* 1995;22(3):802-7. (PMID: 7544756)
20. Khien VV, Mao HV, Chinh TT, et al. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. *Int J Biol Markers* 2001;16(2):105-11. (PMID: 11471892)
21. Hagiwara S, Kudo M, Kawasaki T, et al. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. *J Gastroenterol* 2006;41(12):1214-9. (PMID: 17287901)
22. Tada T, Kumada T, Toyoda H, et al. Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. *Liver Int* 2005;25(4):848-53. (PMID: 15998436)
23. Oka H, Saito A, Ito K, et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. *J Gastroenterol Hepatol* 2001;16(12):1378-83. (PMID: 11851836)
24. Chen H, Zhang Y, Li S, et al. Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma. *Cancer Manag Res* 2018;10:1947-58. (PMID: 30022853)
25. Setsu T, Tsuchiya A, Watanabe T, et al. Early Detection of Hepatocellular Carcinoma Recurrence Using the Highly Sensitive Fucosylated Fraction of Alpha-Fetoprotein. *Case Rep Gastroenterol* 2017;11(1):142-7. (PMID: 28611567)
26. Wongjarupong N, Negron-Ocasio GM, Chaiteerakij R, et al. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. *World J Gastroenterol* 2018;24(12):1321-31. (PMID: 29599607)
27. Toyoda H, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A. Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. *Liver Cancer* 2015;4(2):126-36. (PMID: 26020034)
28. Chaiteerakij R, Zhang X, Addissie BD, et al. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. *Liver Transpl* 2015; 21(5):599-606. (PMID: 25789635)
29. Wang Y, Yang X, Yu Y, et al. Immunotherapy of patient with hepatocellular carcinoma using cytotoxic T lymphocytes ex vivo activated with tumor antigen-pulsed dendritic cells. *J Cancer* 2018;9(2):275-87. (PMID: 29344274)
30. Cheng HT, Chang YH, Chen YY, Lee TH, Tai DI, Lin DY. AFP-L3 in chronic liver diseases with persistent elevation of alpha-fetoprotein. *J Chin Med Assoc* 2007;70(8):310-7. (PMID: 17698430)